HCB-101 is under clinical development by HanchorBio and currently in Phase I for Non-Hodgkin Lymphoma. According to GlobalData, Phase I drugs for Non-Hodgkin Lymphoma have a 72% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how HCB-101’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

HCB-101 overview

HCB-101 is under development for the treatment of advanced solid tumors and relapsed or refractory non-Hodgkin's lymphoma. The therapeutic candidate is an engineered SIRP alpha protein fused to the Fc region of IgG4. It is being developed based on IgG Fc-Based Designer Biologics (FBDB) platform. It is administered by intravenous route.

HanchorBio overview

HanchorBio is a clinical-stage biotechnology company that develops therapies to treat immune-oncology diseases. The company utilizes the IgG Fc-Based Designer Biologics (FBDB) platform that enables biologics with diverse multi-targeting modalities to overcome the challenges of anti-PD1/L1 immunotherapies. It is developing its lead product candidate, HCB101, for the treatment of non-Hodgkin lymphoma and solid tumors; and other pipeline products include HCB301, HCB303, HCB302, SIRPa x anti-CCC FBDB, IL-X FBDB, IL-Y FBDB, and IL-Z FBDB to treat cancer. The company operates in Cayman Islands, Hong Kong, Taiwan, and the US. HanchorBio is headquartered in Taipei City, Taiwan.

For a complete picture of HCB-101’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.